Telomir Pharmaceuticals, Inc. Common Stock Price & Performance (TELO)

Rhumbline Advisers significantly increased its investment in Telomir Pharmaceuticals, Inc., doubling its holdings during the fourth quarter. The firm now owns 8,600 shares, valued at $35,000. This move follows similar activity by other institutional investors, indicating growing interest in the company. Telomir’s stock recently rose by 7.3%, reflecting positive market sentiment.1

Telomir Pharmaceuticals reported that its experimental drug, Telomir-1, reduced tumor growth by 50% in a prostate cancer animal model. The drug also mitigated chemotherapy toxicity, showing no fatalities when combined with Paclitaxel. These results highlight Telomir-1’s potential to enhance cancer treatment and address concerns about telomere-elongating drugs.23

Telomir Pharmaceuticals announced promising findings for Telomir-1 in reversing cellular aging. The drug restored calcium balance and reduced oxidative stress in human cell lines, offering hope for treating age-related diseases. While still preclinical, these results position Telomir-1 as a potential breakthrough in longevity science and therapeutic development.4